(Q36900784)

17 August 2017

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer (English)

1 reference

17 August 2017

1 reference

1 reference

Matthew R Smith

1

1 reference

17 August 2017

S Bruce Malkowicz

2

1 reference

17 August 2017

Michael K Brawer

3

1 reference

17 August 2017

Michael L Hancock

4

1 reference

17 August 2017

Ronald A Morton

5

1 reference

17 August 2017

Mitchell S Steiner

6

1 reference

17 August 2017

language of work or name

English

0 references

publication date

19 October 2011

1 reference

17 August 2017

1 reference

17 August 2017

186

1 reference

17 August 2017

6

1 reference

17 August 2017

2239-2244

1 reference

Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Treatment and prevention of bone complications from prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Redefining hormone resistance in prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Epidemiology and pathophysiology of cancer-associated thrombosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Androgen deprivation therapy for prostate cancer: new concepts and concerns

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Androgen deprivation therapy for prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Statistical aspects of the analysis of data from retrospective studies of disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3671875

Risk of fracture after androgen deprivation for prostate cancer

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22014807

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22014807

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.JURO.2011.07.090

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

22014807

1 reference